REVIEW
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright © 2011 The Korean Society of Cardiology
DOI 10.4070/kcj.2011.41.7.349
Open Access
The Significance of the J-Curve in Hypertension and
Coronary Artery Diseases
Chang Gyu Park, MD, and Ju Young Lee
Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea
ABSTRACT
The J-curve effect describes an inverse relation between low blood pressure (BP) and cardiovascular complications. This effect is more pronounced in patients with preexisting coronary artery disease (CAD), hypertension or left ventricular hypertrophy (LVH). The recent large clinical outcomes trials have observed a J-curve effect between a diastolic BP of 70-80 mmHg
as well as a systolic BP <130 mmHg. The J-curve phenomenon does not appear in stroke or renal disease. This is because the
coronary arteries are perfused during diastole, but the cerebral and renal perfusion mainly occurs in systole. Therefore, caution should be taken to maintain the diastolic blood pressure (DBP) at minimum of 70 mmHg and possibly to maintain the
DBP between 80-85 mmHg in patients with severe LVH, CAD or vascular diseases. BP control in high-risk elderly patients
should be carefully done as undergoing aggressive therapy to lower the systolic blood pressure below 140 mmHg can cause
cardiovascular complications due to the severely reduced DBP and increased pulse pressure. (Korean Circ J 2011;41:349-353)
KEY WORDS: Hypertension; J-curve; Coronary artery disease; Diastolic pressure; Systolic pressure; Stroke.
Introduction
and that was published in 2002 Lancet about hypertension
and mortality was comprised of 61 cohort studies targeting
one million subjects with the support of the British Cardiac
Society. According to the analysis, vascular mortality in coronary artery disease (CAD) and stroke decreased as the systolic BP decreased from 180 mmHg to 115 mmHg and the diastolic BP declined from 100 mmHg to 75 mmHg. Since then,
the principle “the lower, the better” has been widely accepted.
The term “essential hypertension” was first named by Frank a century ago in 1911, and this was based on his perception that hypertension is a disease of increased vascular tone
of the small arteries in the whole body.1) Thus, an increase in
blood pressure (BP) is necessary to maintain blood flow to
target organs through sclerotic arteries. As this notion survived into the 1970s, physicians were reluctant to lower BP in the
elderly patients since they regarded hypertension as being
compensatory in the aging process.2) The concept was strongly believed because excessive reduction of blood in some hypertensive emergencies led to organ damage such as renal
failure, encephalopathy and myocardial ischemia, and the result was stroke, heart attacks and even death.3) However, this
idea gradually changed as treating hypertension showed a
better prognosis. A large meta-analysis by Lewington et al.4)
The J-Curve Concept
Reports warning against aggressive lowering of BP continued to exist. This doubt was based on the evidence that a BP
of 0 mmHg results in 100% mortality. In 1979, after a study
with over 6 years follow-up, Stewart5) reported a 5 times higher risk of myocardial infarction (MI) in hypertensive patients
with a diastolic blood pressure (DBP) less than 90 mmHg
when compared to those with DBP 100-109 mmHg. About 10
years later, Cruickshank6) reported a strong J-curve phenomenon between MI and the DBP in moderate to severe hypertensive patients only when they had CAD. The DBP at the
nadir of the J-curve ranged from 85 to 90 mmHg and the Jcurve did not appear in the absence of CAD. In several studies
conducted afterwards, the J-curve in heart attacks and other
heart diseases was consistently observed whereas no J-curve
Correspondence: Chang Gyu Park, MD, Cardiovascular Center, Korea
University Guro Hospital, 80 Guro-dong, Guro-gu, Seoul 152-703, Korea
Tel: 82-2-2626-3019, Fax: 82-2-863-1109
E-mail: [email protected]
• The authors have no financial conflicts of interest.
cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
349
J-Curve in Hypertension and CAD
Mechanism of the J-Curve and
the Pathophysiologic Approach
Most of the coronary circulation occurs during diastole. During systole, the left ventricular (LV) myocardium contracts
and compresses the intramyocardial vessels to impede its blood flow. If the diastolic pressure is too low, then the myocardial perfusion can be affected. Thus, the J or U curve hypothesis that a DBP less than 70 or 60 mmHg may cause myocardial
ischemia and increase mortality is widely accepted. The coronary perfusion pressure is determined by the gradient between the coronary and LV diastolic pressures. When the coronary perfusion pressure is lowered to 40-50 mmHg, the
blood flow due to coronary perfusion pressure theoretically
approaches 0 with exclusion of the LV diastolic pressure.8)
The myocardium autoregulates the perfusion pressure in
the range of 45 to 125 mmHg,9) and so the myocardium is capable of enduring various degrees of proximal coronary stenosis. However, in CAD patients, compromised autoregulation reduces the perfusion pressure distal to a stenosis when
a decrease in the DBP occurs, resulting in an increased LV
filling pressure. It further decreases the coronary perfusion
pressure to intensify the vicious cycle of myocardial ischemia.
As the LVH gets more severe, the LV endocardial ischemia
worsens and myocardial ischemia occurs even in moderately
low ranges of DBP.10)11)
Reverse causality
Other explanations about the existence of the J-curve have
been proposed. Reverse causality views coexisting chronic illness or a poor health condition as a cause for low DBP, which
leads to increased morbidity and mortality.12-14)
According to Established Populations for Epidemiologic
Studies of the Elderly,15 17% of the population showed a decrease in the systolic blood pressure (SBP) greater than 20
mmHg and 22% showed a reduction of the DBP more than
10 mmHg over 3 years.
The group with reduced DBP showed increased all-cause
mortality by 1.5 fold, increased cardiovascular mortality by
1.6 fold and increased cardiovascular events by 1.4 fold. Yet,
when adjusted for disease and the functional status, there was
no significant relationship between BP reduction and the hazard ratio. That is, reduced BP in the elderly is a common event
indicating a poor sanitary status and health condition, and its
association with increased mortality is an illusion. Such patients generally have a tendency of both low SBP and low
DBP; therefore, the PP is not very high.
Increase in pulse pressure
Low DBP is attributed to progressed vascular disease and
a rise in the PP due to increased aortic stiffness, and this is not
the problem itself. In fact, low DBP is related to the J-curve in
isolated systolic hypertension (ISH) patients, but low DBP is
not related to the J-curve in patients with low SBP. An example is the Systolic Hypertension in the Elderly Program study16) and the Syst-Eur study17) on elderly ISH patients, where
no increase in myocardial ischemia or cardiovascular disease
(CVD) risk was shown at a DBP of 55-60 mmHg.
Major Clinical Studies on the J-Curve
The International Verapamil SR-Trandolapril (INVEST)
study on 22,000 hypertensive patients with CAD compared
verapamil-based treatment and atenolol based treatment and
the initial results were reported in 2003. On the analysis of
the INVEST study by Messerli et al.18) when considering DBP
of 80-90 mmHg as the lowest point, DBP below 70-80 mmHg
shows the J-curve as an increased risk of MI appears (Fig. 1).
Especially, CAD patients are more sensitive to a reduction in
DBP and there is 2-fold CAD risk difference between a DBP
of 80 mmHg and 65 mmHg. The J-curve phenomenon was
observed in CAD, but not in stroke (Fig. 1). The J-curve effect
was more apparent in CAD patients who did not go through
revascularization than those who underwent revasculariza20
Incidence (%) of MI/stroke
was observed in stroke and renal diseases.7)
MI
Stroke
15
10
5
0
≤60
61-70 71-80 81-90 91-100 101-110 >110
Fig. 1. The Incidence of the myocardial infarction and stroke as
stratified by diastolic blood pressure in the International Verapamil
SR-Trandolapril study.18)
6
Patients with revascularization
Patients without revascularization
5
Hazard ratio
350
4
3
2
1
0
55
60
65
70 75
80 85
90
95 100 105 110 115
DBP (mmHg)
Fig. 2. Interaction of the J-Curve with coronary revascularization.
The patients who were revascularized better tolerated a lower diastolic blood pressure (DBP) than those who were not.18)
Chang Gyu Park, et al.
tion (Fig. 2).
In the Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention study,19) a SBP below 120 mmHg showed a J-shaped increase of cardiovascular mortality in the olmesartan group compared to the placebo group. The Treating
to New Targets study20) was conducted to observe the relationship between antihypertensive treatment and the CAD risk in
CAD patients. The SBP and DBP were categorized by a 10
mmHg rise, and the primary end point was set as a major cardiovascular event such as death from CAD, nonfatal MI, resuscitation after cardiac arrest and fatal or nonfatal stroke. After a median follow-up of 4.9 years, the lowest BP with the
lowest incidence of CVD was 146.3/81.4 mmHg. Especially,
a BP less than 110-120/60-70 mmHg showed the J-curve relationship as the incidence of CVD increased. Yet as SBP decreased, the stroke incidence also declined.
According to the Ontarget study21) that targeted the highrisk group, the effect of lowering the SBP was mainly a reduction of the incidence of stroke. As the SBP is reduced below 130 mmHg, there was no difference in the MI incidence whereas there was a J-shaped increase in the CVD mortality. Controlling Blood Pressure
in Diabetes and the J-Curve
The hypertension optimal treatment (HOT) study,22) which
aimed to determine the DBP target in hypertensive patients,
divided approximately 19,000 patients with essential hypertension and who were 50-80 years old (median age: 61.5) into
three levels target DBPs (below 80, 80-85 and 85-90 mmHg)
351
and then treatment was begun. As a result, the incidence of
CVD was lower in the lower target DBP groups, with the lowest incidence for a DBP of 83 mmHg and a SBP of 139 mmHg.
There was no extra benefit in terms of the cardiovascular event
even when the DBP was lowered below 90 mmHg in the nondiabetic patients, but maintaining the DBP below 80 mmHg
in diabetic patients led to about 50% of extra benefit in reducing events. In only the smokers, the J-curve was found in the
group with a target DBP below 80 mmHg as this group showed a 2-fold increase in cardiovascular events compared to the
group with a target DBP below 90 mmHg. Based on these
results, the target BP in hypertensive patients with diabetes
was set as 130/80 mmHg.
However, this is supported by only a few studies, and specifically there is no evidence that using anti-hypertensives in the
patients with BP 130-140/80-90 mmHg offers any extra benefit. The recent data from the Action to Control Cardiovascular
Risk in Diabetes-blood pressure study,23) which investigated
the difference between intensive BP lowering and standard antihypertensive therapy in patients with either diabetes or MI,
in contrast to the expected outcome, showed no significant
difference between the intensive BP lowering group with a
target SBP below 120 mmHg and the standard treatment group with a target SBP below 140 mmHg. In addition, a retrospective analysis of the INVEST trial to examine the benefit
of intensive BP control in diabetic patients with CAD revealed that lowering the BP below 130 mmHg did not offer any
additional benefit and even the J-curve phenomenon was
observed as excessive reduction of BP resulted in a higher
mortality rate (Fig. 3).
1.0
10
0.2
Standard
0.1
Intensive
0.6
0.0
0.4
0.2
0.0
0 1 2
3 4 5
6
7 8
Adjusted hazard ratio
Proportion with event
0.8
1.0
p=0.20
0
1
2
3
4
5
6
7
0.5
8
<110
Years
115-<120
120-<125
125-<130
Systolic blood pressure (mmHg)
No. at risk
Intensive
2,362 2,273 2,182 2,117 1,770 1,080 298
175
080
Standard
2,371 2,274 2,196 2,120 1,793 1,127 358
195
108
A 110-<115
No. at risk
35
98
306
757
1,059
No. of deaths
12
17
038
069
0,112
B Fig. 3. Results of the peoprotion of events in Action to Control Cardiovascular Risk in Diabetes-blood pressure (effects of intensive bloodpressure control in type 2 diabetes mellitus) (A) and the Adjusted risk of all-cause mortality in International Verapamil SR-Trandolapril (B).23)
352
J-Curve in Hypertension and CAD
Studies Contradicting
the J-Curve Concept
observed for patients with DBP below 69 mmHg.
Why Does the J-Curve Appear
in Coronary Artery Disease, but Not
in Stroke or Renal Disease?
Reported in 1995, the 16 years of follow-up study of Multiple Risk Factor Interventional Trial (MRFIT)24) investigated
5,440 patients with prior hospitalization of 2 weeks or more
for MI at the initial screening of MRFIT. In the first 2 years of
the follow-up, all-cause mortality was high in those patients
with a SBP <120 mmHg and those with a DBP <70 mmHg. Afterwards, the lowest SBP and DBP strata showed a decreasing
pattern of mortality. If a low DBP is the cause of death, then
the high mortality rate should have continued for 15 years.
Therefore, the authors stated that the high mortality is not
due to a low diastolic pressure, but rather, it was due to a defect in the LV function that led to lower DBP and SBP. It has
also been suggested that the low DBP results from LV dysfunction and a reduced stroke volume and this leads to increased
mortality.
Glynn et al.25) followed 22,071 men and 39,876 women in
the PHS and WHS for a median of 13.0 years and 6.2 years,
respectively, and they observed an association of the SBP and
DBP with the risk of MI, stroke, coronary artery bypass, angioplasty and cardiovascular death. In this study, both women and men with lower SBP had a lower incidence of CVD
and they did not show the J-curve relationship. There was a
gender difference in DBP, as a lower DBP reduced CVD with
a slight J-curve shown below 60 mmHg in men, but there was
no association or the J-curve relationship between the DBP
and CVD observed in the women.
The HOT study, consistent with the study of Cruickshank
et al.6) reported a J-shaped relationship between DBP below
85mmHg and the risk of MI only in the patients with CAD,
but not in those without CAD.
According to the Cardiovascular Health Study by Psaty et
al.26) the BP level and CVD risk showed a linear relationship
and the J-curve between DBP and incidence of MI was not
Coronary perfusion occurs in diastole, whereas cerebral
perfusion mainly occurs in systole. Cerebral perfusion is capable of autoregulation in the range of 40-125 mmHg, so it is
resistant to low BP. As a result, the J-curve phenomenon does
not hold true for the incidence of stroke. Renal perfusion also
occurs mainly in systole, and so no J-curve is observed as well.
Realistic Approach to
Manage the J-Curve
Even today, the J-curve phenomenon in antihypertensive
therapy is still controversial and there have been only limited
studies on its relation to SBP. In light of the results from previous several studies, the occurrence of increased myocardial ischemia resulting from aggressive lowering of the DBP
should be considered during antihypertensive therapy. Although most of the studies have shown the J-curve for DBP
below 70-80 mmHg, this phenomenon does not appear in
stroke or renal disease. Therefore, since the appearance of the
J-curve in patients with clinically severe LVH, CAD or vascular diseases is highly probable, caution should be taken to maintain the DBP at minimum of 70 mmHg and possibly to
maintain the DBP between 80-85 mmHg.
The SBP is suggested to be controlled according to a rule
“moderation is the best thing”, rather than the old golden rule
“the lower the better”. In other words, as 2009 revised European Guidelines on Hypertension Management27) stated, maintaining a BP of 130-139/80-85 mmHg in patients with hypertension seems to be appropriate using the current evidencebased medicine (Fig. 4). Since ISH patients already have low
Diabetes mellitus
170
160
SBP (mmHg)
150
140
BP Δ
Benefit
Partial benefit
No benefit
162
155
154
148
143
145
145
144
153
138
139
130
132
120
137
144
144
145
140
141
143
143
134
140
134
130
128
110
100
HOT
UK
SHEP
S.Eur
MHOPE
ABCD
HT
NT
IDNT
IR
AM
REN
ADV
PROG
Fig. 4. The pre- and post-treatment systolic blood pressure clinical benefit in a clinical hypertension study on diabetic patients.18)
Chang Gyu Park, et al.
DBP in many cases and the PP reduction by decreasing the
SBP has benefits for preventing CVD that outweigh the risks
caused by a reduced DBP, based on the Syst-Eur study,17) lowering the SBP while maintaining the DBP above 55-60 mmHg
is suggested if the patients do not have CAD. If they have coexisting vascular diseases like CAD, then BP control is suggested after reperfusion procedures such as PCI or CABG. A
careful approach should be used for BP control in high-risk
elderly patients as undergoing aggressive therapy to lower the
SBP below 140 mmHg can cause cardiovascular complications due to the severely reduced DBP and increased PP.
Conclusion
The current national and international antihypertensive treatment guidelines recommend a BP goal of <140/90 mmHg,
and <130/80 mmHg in patients with CAD, chronic renal
disease and other CVD. However, the recent large clinical studies have shown the J-curve phenomenon in patients with a
DBP <80 mmHg as well as in patients with a SBP <130
mmHg, and the studies demonstrated no significant differences in the risk of cardiovascular complications between aggressive antihypertensive therapy and standard therapy. Yet
the J-shaped curve does not appear for stroke patients, and
this shows a relationship consistent with the principle “the
lower the better”.
REFERENCES
1)Frank E. Deutsches archiv fur klin. Medizin 1911;103:397-412.
2)White P. Heart Disease. 1st ed. New York: McMillan;1931.
3)Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive
emergencies and pseudoemergencies? JAMA 1996;276:1328-31.
4)Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific
relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
Lancet 2002;360:1903-13.
5)Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979;1:861-5.
6)Cruickshank JM, Thorp JM, Zacharias EJ. Benefits and potential
harm of lowering high blood pressure. Lancet 1987;1:581-4.
7)Farnett L, Muldrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve
phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA 1991;265:489-95.
8)Bellamy RF. Diastolic coronary artery pressure flow relations in the dog.
Circ Res 1978;43:92-101.
9)Pijls NHJ, De Bruyne B. Pitfalls in coronary pressure measurements.
In: Coronary pressure. Dortrecht: Kluwer Academic Publishers; 1997.
p.105-8.
353
10)Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML.
The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation 1988;77:1108-15.
11)Polese A, De Cesare N, Montorsi P, et al. Upward shift of the lower
range of coronary flow autoregulation in hypertensive patients with
hypertrophy of the left ventricle. Circulation 1991;83:845-53.
12)Hakala SM, Tilvis RS. Determinants and significance of declining
blood pressure in old age: a prospective birth cohort study. Eur Heart
J 1998;19:1872-8.
13)Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganiats TG.
Blood pressure change and survival after age 75. Hypertension 1993;
22:551-9.
14)Tervahauta M, Pekkanen J, Enlund H, Nissinen A. Change in blood
pressure and 5-year risk of coronary heart disease among elderly men:
the Finnish cohorts of the Seven Countries Study. J Hypertens 1994;12:
1183-9.
15)Satish S, Zhang DD, Goodwin JS. Clinical significance of falling blood pressure among older adults. J Clin Epidemiol 2001;54:961-7.
16)Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The
role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1991;159:2004-9.
17)Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood
pressure and prognosis in systolic hypertension. Arch Intern Med
2007;167:1884-91.
18)Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary
artery disease be dangerous? Ann Intern Med 2006;144:884-93.
19)Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:
907-17.
20)Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New
Targets (TNT) Trial. Eur Heart J 2010;31:2897-908.
21)Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial Study.
J Hypertens 2009;27:1360-9.
22)Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT)
randomized trial: HOT Study Group. Lancet 1998;351:1755-62.
23)Cushman WC, Evans GW, Byington RP, et al. Effects of intensive
blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;
362:1575-85.
24)Flack JM, Neaton J, Grimm R Jr, et al. Blood pressure and mortality
among men with prior myocardial infarction: Multiple Risk Factor Intervention Trial Research Group. Circulation 1995;92:2437-45.
25)Glynn RJ, L’Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002;39:
105-10.
26)Psaty BM, Furberg CD, Kuller LH, et al. Association between blood
pressure level and the risk of myocardial infarction, stroke, and total
mortality: the Cardiovascular Health Study. Arch Intern Med 2001;
161:1183-92.
27)Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58.